Anavex Life Sciences Corp. (AVXL) |
|
12.38 -0.27 (-2.13%)
|
01-21 17:31 |
|
Open: |
12.5 |
Pre. Close: |
12.65 |
|
High:
|
13 |
Low:
|
12.29 |
|
Volume:
|
1,185,495 |
Market Cap:
|
941M |
|
|
|
|
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.016 - 13.097 |
13.097 - 13.154 |
|
Low:
|
12.103 - 12.201 |
12.201 - 12.271 |
|
Close:
|
12.251 - 12.395 |
12.395 - 12.496 |
|
Technical analysis |
as of: 2022-01-21 4:24:57 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 19.80  One year: 23.16 |
| Support: |
Support1: 12.29 Support2: 10.23 |
| Resistance: |
Resistance1: 16.95 Resistance2: 19.83 |
| Pivot: |
14.89 |
| Moving Average: |
MA(5): 13.24 MA(20): 15.73
MA(100): 18.26 MA(250): 16.87  |
| MACD: |
MACD(12,26): -1.48 Signal(9): -1.19 |
| Stochastic oscillator: |
%K(14,3): 3.44 %D(3): 4.90 |
| RSI: |
RSI(14): 27.23 |
| 52-week: |
High: 31.50 Low: 6.12 Change(%): 105.3 |
| Average Vol(K): |
3-Month: 956 10-Days: 1036 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.AVXL has closed above bottom band by 8.9%. Bollinger Bands are 51.8% wider than normal. The large width of the bands suggest high volatility as compared to Anavex Life Sciences Corp.'s normal range. The bands have been in this wide range for 9 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 06 Jan 2022
Anavex Life Sciences Promotes Walter E Kaufmann, MD to - GlobeNewswire
Mon, 03 Jan 2022
When Can We Expect A Profit From Anavex Life Sciences Corp. (NASDAQ:AVXL)? - Nasdaq
Sun, 19 Dec 2021
Zacks: Brokerages Anticipate Anavex Life Sciences Corp. (NASDAQ:AVXL) Will Post Earnings of -$0.16 Per Share - MarketBeat
Tue, 14 Dec 2021
Anavex Life Sciences to Present at 40th Annual JP Morgan - GlobeNewswire
Wed, 24 Nov 2021
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results - GlobeNewswire
Mon, 01 Nov 2021
Anavex Life Sciences Corp (AVXL) has fallen 6.88% Monday In Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
76 |
| Shares Float (M) |
74 |
|
% Held by Insiders
|
3.20 |
|
% Held by Institutions
|
28.13 |
|
Shares Short (K)
|
4,500 |
|
Shares Short P. Month (K)
|
4,810 |
Stock Financials |
|
EPS
|
-0.540 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
1.990 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-23.9 |
|
Return on Equity (ttm)
|
-42.6 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-30 |
|
Levered Free Cash Flow (M)
|
-16 |
Stock Valuations |
|
PE Ratio
|
-22.93 |
|
PEG Ratio
|
|
|
Price to Book value
|
6.22 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
